Blastic plasmacytoid dendritic cell neoplasm
Revision as of 14:11, 15 September 2022 by Warner-admin (talk | contribs) (Text replacement - "https://www.nejm.org/doi/full/10.1056" to "https://doi.org/10.1056")
1 regimens on this page
1 variants on this page
|
All lines of therapy
Tagraxofusp monotherapy
Regimen
Study | Years of enrollment | Evidence |
---|---|---|
Frankel et al. 2014 (STU 012013-061) | 2013-NR | Phase 1/2, <20 pts |
Pemmaraju et al. 2019 (STML-401-0114) | 2014-2017 | Phase 1/2 (RT) |
Targeted therapy
- Tagraxofusp (Elzonris) 12 mcg/kg IV over 15 minutes once per day on days 1 to 5
21-day cycles
References
- STU 012013-061: Frankel AE, Woo JH, Ahn C, Pemmaraju N, Medeiros BC, Carraway HE, Frankfurt O, Forman SJ, Yang XA, Konopleva M, Garnache-Ottou F, Angelot-Delettre F, Brooks C, Szarek M, Rowinsky E. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014 Jul 17;124(3):385-92. Epub 2014 May 23. link to original article link to PMC article PubMed NCT00397579
- STML-401-0114: Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, Rizzieri DA, Wang ES, Duvic M, Sloan JM, Spence S, Shemesh S, Brooks CL, Balser J, Bergstein I, Lancet JE, Kantarjian HM, Konopleva M. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2019 Apr 25;380(17):1628-1637. link to original article contains dosing details in manuscript PubMed NCT02113982